Delivery Order SPE2DB24D2100-SPE2DB25FBFSV
- Not listed
- The Defense Logistics Agency awarded a $3,689.75 firm fixed-price delivery order to AmerisourceBergen Drug Corp for Entresto 24 mg-26 mg tablets (60-count supply) on July 18, 2025, with an ultimate completion date of July 21, 2025. This non-competitive delivery order was placed against AmerisourceBergen's substantial Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026. The order will be fulfilled at...
- The Defense Logistics Agency awarded a delivery order valued at approximately $24,925 to AmerisourceBergen Drug Corp for the supply of Entresto 24 mg-26 mg tablets (180 count) under a firm fixed-price contract. The award was made on August 15, 2025, with an ultimate completion date of August 18, 2025, and represents a non-set-aside competitive procurement. AmerisourceBergen's corporate office in Conshohocken, Pennsylvania served as the place of performance for this pharmaceutical delivery order....
- The Defense Logistics Agency awarded a delivery order valued at $43,457.38 to AmerisourceBergen Drug Corp for Entresto 49 mg-51 mg tablets (60-count units) on August 25, 2025, with an ultimate completion date of August 26, 2025. This competitively awarded, firm fixed-price delivery order is non-set-aside and represents pharmaceutical procurement under AmerisourceBergen's existing Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), a $999.9 billion global pharmaceutical...
- The Defense Logistics Agency awarded a delivery order valued at $13,992.61 to AmerisourceBergen Drug Corp for the supply of Entresto 24 mg-26 mg tablets (180-count units) on July 28, 2025, with an ultimate completion date of July 29, 2025. This firm fixed-price delivery order was competitively awarded with no set-aside designation and will be performed at the contractor's facility in Conshohocken, Pennsylvania. AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare...
- The Defense Logistics Agency awarded a delivery order valued at $13,183.45 to AmerisourceBergen Drug Corp for the supply of Entresto 24 mg-26 mg tablets (60-count units) under a firm fixed-price contract. The award, issued on August 21, 2025, with an ultimate completion date of August 22, 2025, represents a non-competitive delivery order utilizing the company's existing pharmaceutical supply agreement. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, serves as a critical vendor in...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 18, 2025, for the supply of Entresto 49 mg-51 mg tablets (180-count supply) with a ceiling value of $51,539.65. This is a firm fixed-price delivery order with an ultimate completion date of July 21, 2025, and represents a competitively awarded contract with no set-aside designation. The work will be performed in Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate headquarters...
- The Defense Logistics Agency awarded a delivery order valued at $66,325.99 to AmerisourceBergen Drug Corp for the supply of Entresto 24 mg-26 mg tablets (180-count packages) under a firm fixed-price contract. The award was issued on August 15, 2025, with an ultimate completion date of August 18, 2025, and represents a non-competitive delivery order. Performance will occur at the contractor's facility in Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate headquarters as a...
- The Defense Logistics Agency awarded a delivery order valued at $14,418.82 to AmerisourceBergen Drug Corp for the supply of Entresto 24 mg-26 mg tablets (60-count units). Issued on August 25, 2025, with an ultimate completion date of August 26, 2025, this firm fixed-price contract represents a competitively awarded, non-set-aside procurement executed through the company's existing indefinite delivery contract vehicle with DLA. The product will be delivered to AmerisourceBergen's corporate office...
- The Defense Logistics Agency awarded a delivery order valued at $7,134.39 to AmerisourceBergen Drug Corp for the supply of Entresto 24 mg-26 mg tablets in a quantity of 60 units. This competitive award, executed on August 22, 2025, with an ultimate completion date of August 25, 2025, represents a firm fixed price delivery order with no set-aside designation. The pharmaceutical product will be delivered to AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for the supply of Entresto 24 mg-26 mg tablets (180-count) with a ceiling value of $1,984.24. This non-set-aside, competitively awarded delivery order reflects a firm fixed price contract structure and is scheduled for completion by August 21, 2025. The contract will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, where the company maintains its primary operations...
- SPE2DB24D2100Indefinite Delivery Contract
- SPE2DB24D2100-SPE2DB25FBFSVDelivery Order
The Defense Logistics Agency awarded a delivery order valued at $18,266.38 to AmerisourceBergen Drug Corp for the supply of Entresto 24 mg-26 mg tablets (60-count units) under a firm fixed price contract. The award was made on August 7, 2025, with an ultimate completion date of August 8, 2025, and represents a non-set-aside, competitively awarded transaction. Performance will be executed from AmerisourceBergen's location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 through December 2026. As a major pharmaceutical distributor and critical vendor for federal medical procurement, AmerisourceBergen supplies a comprehensive range of pharmaceuticals and medical supplies to support military and veteran healthcare systems. The Entresto tablets being procured under this delivery order are cardiac medications used to treat heart failure, reflecting the company's role in supplying specialized pharmaceutical products across multiple therapeutic domains to support Defense Health Agency and other federal healthcare programs.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $18.3k | 8/7/25 |